Background: Platelets play a pivotal role in the pathogenesis of acute coronary syndrome (ACS) and acute or chronic complications following percutaneous coronary intervention (PCI) as well.
BACkgROuND
Platelets play a pivotal role in the pathogenesis of acute coronary syndrome (ACS) and acute or chronic complications following percutaneous coronary intervention (PCI) as well. Platelet inhibition is a cornerstone treatment in the management of these patients. Thrombocytopenia in patients with ACS is uncommon. Idiopathic thrombocytopenic purpura (ITP) is a rare phenomenon; nevertheless, some case series presenting concomitant ACS and ITP have been described in the literature. The safety of antiplatelet therapy and PCI in patients who have ACS and thrombocytopenia is limited.
CASE PRESENTATION
A 60-year-old Caucasian male with a history of hypertension, hypercholesterolemia, diabetes mellitus, and family history of ischemic heart disease was admitted to our hospital with an increasing chest pain and dyspnea on exertion and sometimes even at rest. Additionally, he was also known to suffer from chronic asymptomatic ITP during the past twenty years, and stable platelet count was around 30 × 10 9 /L without any medical treatment. 
DISCuSSION
Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor antagonist is a fundamental component of ACS management. 1, 2 The management of antiplatelet therapy in ACS patients with thrombocytopenia poses a particular challenge for physicians, as they are at higher risk of both bleeding and, paradoxically, ischemic events. [3] [4] [5] The cause of coronary thrombosis in patients with thrombocytopenia is debatable and multifactorial. Independently of their thrombocytopenia, patients may be predisposed to coronary thrombosis because their platelets are larger and more adhesive to the vascular surface. [6] [7] [8] Evidence supports the concept that large platelets have a higher thrombotic potential. 9 Because platelet production is naturally regulated to maintain platelet mass (the product of platelet count and mean platelet volume), it can be inferred that the larger platelets not only provide a hemostatic plug and prevent bleeding via high activity, but also that they may be linked to coronary thrombosis in patients with thrombocytopenia. There is substantial evidence that microparticles derived from platelets play a role in the activation of the coagulation cascade.9 Levels of platelet microparticles are significantly higher in patients who have ITP than in control groups as well as in ACS patients. 10, 11 There are few reports, mainly on critically ill hemato-oncological patients, which describe the use of antiplatelet agents with no bleeding sequelae thrombocytopenia. 12, 13 Antiplatelet therapy in the presence of thrombocytopenia is debatable, and there are no widely accepted protocols. 14 The current recommendation is to avoid giving antiplatelet agents to patients with ACS who have severe thrombocytopenia (i.e. platelet count <50 × 10 9 /L). 15 The presence of thrombocytopenia in ACS patients predicts significantly worse outcomes. 16, 17 The association of thrombocytopenia and increased ischemic events remains poorly understood. It may reflect the presence of a greater degree of comorbidities that are unmeasured. 18, 19 Which DAPT is preferable in these patients is still unknown.
Clopidogrel offers a lower bleeding risk than ticagrelor or prasugrel, and, accordingly, would be the agent of choice in patients receiving DAPT. 3 Management should begin with the identification and correction of any reversible causes of thrombocytopenia. 18 It is advised to avoid prasugrel and ticagrelor due to their association with higher bleeding rates, although ticagrelor monotherapy, with its twice daily dosing and reversible binding, would be of great interest. 15 Thrombocytopenia may be associated with more concurrent diseases and mechanisms of pro-thrombosis, including ACS. Approaches to the treatment of ACS in thrombocytopenic patients might be better directed toward the evaluation of platelet function than toward platelet count. 20 No doubt, the management of immune thrombocytopenic purpura and acute coronary syndrome is a double-edged sword. 13 However, thrombocytopenia is somehow reversible with the mainstay of the treatment:
prednisolone, azathioprine, IVIG, and romiplostim. 13, 21 Our patient was treated by high-dose prednisone, and successful PCI to RCA was performed. He was discharged with high-dose steroids and DAPT for 6 months. No bleeding occurred during follow-up, and the platelet count level was stabilized around 70 × 10 9 /L. The treatment of the ITP was switched to azathioprine with a good response.
CONCLuSIONS
Patients with ITP and concomitant ACS are rare; nevertheless, definite treatment guidelines for these patients have not been established. We have performed coronary CTA first in order to establish the definite diagnosis and avoid an unnecessary invasive procedure, especially when the urgent procedure cannot be performed and while correcting the hematologic parameters. The case we have reported suggests that PCI is a suitable treatment for ITP patients with ACS. Hemostasis is the major concern in managing these patients. The risk and benefit of long-term antiplatelet agent use should be considered in each patient and should be individualized. The treatment strategy may be based on platelet function rather than on platelet count alone. Further analysis of antiplatelet therapies as mono or dual therapy are needed.
